結核病診治指引(第五版)

參考文獻 1. Toman K. Tuberculosis Case-Finding and Chemotherapy. Question and Answers. 2nd ed. World Health Organization, Geneva, 2004: 152-8.

2. Singh J, Garg PK, Tandon RK. Hepatotoxicity due to antituberculosis therapy. Clinical profile and reintroduction of therapy. J Clin Gastroenterol 1996; 22: 211-4.

3. Thompson NP, Caplin ME, Hamilton MI, et al. Anti-tuberculosis medication and the liver: dangers and recommendations in management. Eur Respir J 1995;8:1384-8.

4. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America. Treatment of tuberculosis. Am J Respir Crit Care Med 2003;167:603–62.

5. Ormerod LP, Skinner C, Wales J. Hepatotoxicity of antituberculosis drugs. Thorax 1996; 51: 111-3.

6. Joint Tuberculosis Committee of the British Thoracic Society. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Thorax 1998;53: 536-48.

7. Ellard G, Haslam R. Observations on the reduction of the renal elimination of urate in man caused by the administration of pyrazinamide. Tubercle 1976; 57: 97-103.

8. Pozniak AL, Miller RF, Lipman MCI, et al. BHIVA Treatment Guidelines for TB/HIV Infection. 2005: 27-9.

9. Guidelines for the programmatic management of drug-resistant tuberculosis: emergency update 2008. Geneva, World Health Organization, 2008 (WHO/HTM/TB/ 2008.402).

10. Treatment of tuberculosis: guidelines – 4th ed. Geneva, World Health Organization, 2009 (WHO/HTM/TB/2009.420).

11. Lienhardt C, Vernon A, Raviglione MC. New drugs and new regimens for the treatment of tuberculosis: Review of the drug development pipeline and implications for national programmes. Curr Opin Pulm Med. 2010;16:186-193 12. Tuberculosis Drug Information Guide. Francis J. Curry National Tuberculosis Center and California Department of Public Health, 2009.

13. A Tuberculosis guide for specialist physicians, IUATLD, 2003: 159, Table 7.

78